TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Electromyography and Acceleromyography in Ventilated ICU Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 yr. old or older~* expected to require mechanical ventilation for more than 72 hrs~Exclusion Criteria:~* degenerative neurological disease~* receive drugs interfering with NMT (e.g., aminoglycosides or magnesium)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- electromyographic NMT monitoring at the hand (Type: EXPERIMENTAL): In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
- acceleromyographic NMT monitoring at the hand (Type: EXPERIMENTAL): In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
- acceleromyographic NMT monitoring at the eyebrow (Type: EXPERIMENTAL): In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Performance of Continuous Glucose Monitoring Systems at Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 60 years.~* No known medical conditions or concomitant medication.~Exclusion Criteria:~* Pregnancy.~* Marine diving in preceding 24 hours.~* Unable to provide written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CGMS at sea level. (Type: ACTIVE_COMPARATOR): To assess reliability of continuous glucose monitoring system at sea level whilst subject undergo's a hyperinsulinaemic glucose clamp study.
- CGMS reliability at simulated 8000 feet. (Type: ACTIVE_COMPARATOR): To assess reliability of continuous glucose monitoring system at a simulated altitude of 8,000 feet whilst the participant undergo's a hyperinsulinaemic glucose clamp study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Obtained informed consent~* Leg or foot arterial or mixed ulcer older than at least 3 months~Exclusion Criteria:~* No obtained informed consent~* Possibility for surgical treatment (revascularisation)~* Age less than 18~* Pregnancy~* Indication for major amputation (below /above the knee)~* Venous ulcer~* Ulcer with infection and / or necrosis~* Mycotic ulcer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amniotic membranes (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of clinically-definite relapsing-remitting multiple sclerosis~Exclusion Criteria:~* Any Product Information-specified contraindications to interferon-beta therapy, or other medical factors which, in the opinion of the investigator, make the subject unsuitable for interferon-beta therapy~* Use of AVONEX, but not other interferon therapies, in the 3 months prior to randomisation into the study~* A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to randomisation.~* History of seizure in the 3 months prior to randomisation~* History of suicidal ideation or severe depression within the 3 months prior to randomisation.~* Other inclusion and exclusion criteria may apply per study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): titrated dose of Avonex
- 2 (Type: ACTIVE_COMPARATOR): full dose Avonex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Moderate, non-fistulizing Crohn's disease in the ileum and/or colon prior to randomization; and a SES-CD score of ≥7 (confirmed by centralized endoscopy reading).~* During the screening period, the participant will need to have certain average daily scores for abdominal pain and average number of liquid/very soft stools.~Major Exclusion Criteria:~* Pregnant or lactating females. Females of childbearing (reproductive) potential must have a negative serum pregnancy test at screening and agree to use a highly effective method(s) of contraception throughout their participation in the study. Diagnosis of ulcerative or indeterminate colitis.~* Diagnosis of Celiac Disease.~* Bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed likely for Crohn's disease during the study period.~* Presence of an ileostomy or colostomy.~* Known fixed symptomatic stenosis/stricture of the small or large bowel.~* Had more than one segmental colonic resection.~* Had more than 3 small bowel resections or symptoms associated with short bowel syndrome.~* Current evidence of peritonitis.~* History or evidence of colonic mucosal dysplasia.~* History or evidence of adenomatous colonic polyps that have not been removed.~* Unwilling to be tapered off corticosteroids by Week 8 or the participant is known by the Investigator to be steroid-dependent.~* Has used a biologic within 12 weeks of randomization.~* Used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs within 8 weeks prior to randomization.~* Had rectal administration of 5-aminosalicylic acid (5-ASA) or corticosteroid enemas/foams/ suppositories within 2 weeks prior to screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin EIR 800 mg (Type: EXPERIMENTAL): Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the Prostate~* Metastatic Disease with at least one lesion on bone scan and/or soft tissue on CT/MRI~* Demonstrated progression on abiraterone and/or enzalutamide~* Demonstrated PSA progression within 12 weeks of study participation~* Castrate testosterone levels at screening with continued Luteinizing hormone-releasing hormone (LHRH) therapy~* Eastern Cooperative Oncology Group (ECOG) score between 0-1~* Asymptomatic or mildly symptomatic~Exclusion Criteria:~* Candidates for cytotoxic chemotherapy~* Received more than one line of chemotherapy~* Received more than one treatment course of enzalutamide or abiraterone~* Inadequate washout of prohibited hormonally active agents or other prior treatments for prostate cancer (PCa)~* Known intra-cerebral disease or brain mets~* Spinal cord compression within 6 months~* Prior treatment with investigative androgen receptor (AR) agents

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EPI-506 (Type: EXPERIMENTAL): Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Analgesia Following Uterine Artery Embolization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult female patients (\>18 years of age) who are undergoing elective uterine artery embolization will be included in the study.~Exclusion Criteria:~* Exclusion criteria for the study are patient refusal to be included in the study, the presence of language barrier that inhibits proper communication with the patient~* Contraindications to regional anesthesia~* History of allergy to amide local anesthetics or narcotics~* Known hypersensitivity to pregabalin, creatinine clearance ≤ 60 mL/min~* The presence of a progressive neurological deficit~* The presence of chronic opioid analgesia~* The presence of a coagulopathy or infection, pregnancy~* Patients with cardiovascular disease~* Patients who take daily antiplatelet medications, patients with peptic ulcer disease~* History of psychiatric disorder or inability to follow study protocol.~* Dropout criteria include failed epidural analgesia, inability to tolerate side effects (nausea) from pregabalin, and the inability to contact during follow up.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin/celecoxib group (Type: ACTIVE_COMPARATOR): pregabalin/celecoxib twice a day for 13 days.
- Pregabalin/placebo group (Type: ACTIVE_COMPARATOR): pregabalin/placebo twice a day for 13 days.
- Celecoxib/placebo group (Type: ACTIVE_COMPARATOR): celecoxib/placebo twice a day for 13 days.
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo group, two placebo tablets day of surgery and twice a day for 13 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age from 18-80 years~2. NIHSS ≥ 1~3. Diagnosis of acute ischemic stroke within 72 hours from stroke onset~4. Enrollment into the study within 24 hours after hospital arrival~5. Urine specific gravity level \< 1.030~6. Patient consent~Exclusion Criteria:~1. Patients receiving \> 40 ml/hr IV fluid infusion over 3 hours~2. Acute ischemic stroke caused cardiogenic embolism~3. Urine specific gravity ≥ 1.030~4. Large cerebral infarction area~   1. Infarction \> 1/3 of middle cerebral artery area~  2. Infarction \> 1/2 of cerebellar hemisphere~5. NHISS ≥ 18~6. Previous or current episode of atrial fibrillation~7. Previous or current episode congestive heart failure~8. Previous echocardiogram with ejection fraction \< 40%~9. Previous or current episode of dilated cardiomyopathy~10. Abnormal renal function GFR ≤ 60% or serum creatinine ≥ 2~11. Modified Rankin scale before acute ischemic stroke ≥ 2~12. Patients receiving intravenous thrombolysis~13. NPO with need for IV fluid~14. IV fluid infusion needed from any other causes~15. Patients with poor prognosis with life expectancy \< 90 days~16. Patients involved in other ongoing clinical studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV Fluid (Type: EXPERIMENTAL): 0.9% NaCl solution infusion: 100 ml/hr for three days.
- No IV Fluid (Type: NO_INTERVENTION): Not receive any intravenous fluid but can consume oral fluid normally for three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: US Guided GNB vs Saline Injection for TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants 40 to 85 years old who are presenting for minimally invasive total knee arthroplasty under spinal anesthesia and are candidates for peripheral nerve blocks.~* Minimally invasive is defined as custom modified instrumentation, a quadriceps sparing arthrotomy that does not extend beyond 1cm proximal to the patella and surgical techniques that focus on soft tissue protection.~Exclusion Criteria:~* Patient refusal~* American Society of Anesthesiologists physical status classification of 4 or higher~* Pre-existing neuropathy in the femoral or sciatic distribution~* Coagulopathy~* Infection at the site~* Chronic opioid use (greater than 3 months)~* Pregnancy~* Medical conditions limiting physical therapy participation~* Any other contra-indication to regional anesthesia

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Patient will receive genicular nerve block with bupivacaine
- Group 2 (Type: PLACEBO_COMPARATOR): Patient will receive normal saline as the nerve block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Presentation with an isolated proximal humeral fracture after a low-energy trauma (e.g. falling from a standing position) and:~* indication for open reduction and internal fixation with a proximal humeral locking plate (PHILOS®, Synthes, Switzerland) after low energy trauma~  * displacement of more than 1 cm between fragments and/or~ * angulation of 45° or more between the fragments and/or~ * dislocation of the greater tuberosity of 5 mm or more and/or~ * patient specific factors like high functional demand etc~* age \> 50 years~* postmenopausal status (i.e. 12 continuous month without menstruation)~* informed consent in surgery and study participation~Exclusion Criteria:~* Psychiatric disorder severely impairing co-operation (dementia mini mental Status (MMS) \<24, schizophrenia, major depression)~* Pathological fractures caused by other conditions~* Fracture-related nerve injury~* Malignancies under current treatment (i.e. chemotherapy, radiotherapy etc.)~* BMI \<20 kg/m2~* Known hypersensitivity to one of the graft components~* Participation in a clinical trial within 3 month before enrolment

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cellularized composite graft augmentation (Type: EXPERIMENTAL): lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
- Control acellular composite graft augmentation (Type: ACTIVE_COMPARATOR): open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A histologic diagnosis of malignancy;~* At planned initiation of a new systemic chemotherapy regimen (including patients starting on first chemotherapy or patients previously treated but starting on a new regimen);~* A risk score for VTE ≥3 \[assign score of 2 for very high risk sites of cancer (stomach, pancreas), score of 1 for high risk site (lung, lymphoma, gynecologic, bladder, testicular) and score of 0 for all other sites\], hemoglobin \<10 g/dL or planned use of erythropoiesis stimulating agents, platelet count ≥350,000/mm3, total leukocyte count \> 11,000/mm3 or body mass index ≥ 35 kg/m2\]. Any counts meeting criteria drawn within 2 weeks prior to enrollment are considered acceptable.~* Age 18 years or older~* Provide written, informed consent.~Exclusion Criteria:~* Active bleeding or at high risk of serious bleeding complication in the opinion of the investigator~* Diagnosis of primary brain tumor multiple myeloma, leukemia, or myelodysplastic syndrome~* Planned stem cell transplant~* Life expectancy \< 6 months~* Known allergy to heparin or LMWH~* Patient or caregiver incapable of daily self-injection~* Acute or chronic renal insufficiency with creatinine clearance \< 30 mL/min~* History of heparin-induced thrombocytopenia~* Allergy to contrast agents~* Pregnancy~* Need for anticoagulant therapy~* Platelet count \< 75,000/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Risk for VTE recieving dalteparin (Type: EXPERIMENTAL): Patients assigned at random to receive prophylactic dalteparin injections
- High Risk for VTE No therapy (Type: NO_INTERVENTION): No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
- Low Risk for VTE (Type: NO_INTERVENTION): Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 antibody positive~* On a virologically suppressive regimen for at least 24 weeks and stable on a PI/r (ATV, LPV or DRV) plus Truvada or Kivexa for at least 4 weeks prior to screening~* Current HIV-1 RNA \<50cps/ml plasma on 2 occasions \>4 weeks apart~* No prior CCR5 or CXCR4 antagonist use~* Prior tetanus toxoid immunisation or known tetanus antibodies. Immunisation must have taken place in the past 10 years, but not within 1 month of baseline visit.~* Known CD4 nadir~* If the subject is a woman of child bearing potential, she must agree to use a double barrier method of contraception~* Willing and able to provide written informed consent~* At least 18 years old~Exclusion Criteria:~* Current or prior immunologically active agents (use of IL-2, GH or GHRH, corticosteroids (except inhaled), G- and GM-CSF) deemed to potentially impact study results.~* History of HIV, cholera or meningococcal immunisation~* Other known immune deficiency or use of immune suppressant~* History of malignancy (except low volume Kaposi's sarcoma) or chemotherapy~* Contraindication to maraviroc~* Peanut or soya allergy~* Antiretroviral agents other than those in inclusion list~* Drugs known to reduce exposure to maraviroc (CYP3A inducers)~* Contraindication to vaccines or vaccine components and/or components of skin test kits~* Pregnant or lactating or planning to become pregnant during the study period~* Acute feverish, stomach or intestinal illness~* Received an investigational medicinal product as part of a clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Nadir CD4 count \>200 cells/µl blood and randomised to Maraviroc 150mg BD
- Group 2 (Type: PLACEBO_COMPARATOR): Nadir CD4 count \>200 cells/µl blood and randomised to placebo twice daily for 24 weeks
- Group 3 (Type: ACTIVE_COMPARATOR): Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
- Group 4 (Type: PLACEBO_COMPARATOR): Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues